Business Wire

SDS (Software Daten Service) Achieves Oracle Exadata Optimized Status

2.11.2020 15:30:00 EET | Business Wire | Press release

Share

SDS today announced it has earned Oracle Exadata Optimized status through Oracle PartnerNetwork (OPN), demonstrating that SDS GEOS 7.9.0 has been tested and tuned on Oracle Exadata Database Machine to deliver speed, scalability, and reliability to customers. SDS is a Platinum level member of OPN.

Only a few companies manage to set new digital standards with the disruptive change happening in the financial industry and at the same time guarantee security in maximum performance dimensions. As part of a proof of concept (PoC) conducted at the Oracle Solutions Center, the throughput of SDS GEOS securities order processing was measured. The test of SDS GEOS 7.9.0 was conducted on an Oracle Exadata X8M configured as a database system with a two-node RAC, with a total of 32 CPU cores and 64GB memory assigned to the workload, which resulted in a more than convincing throughput of 795.9 orders/sec compared to the currently acceptable 100 to 400 orders per second. This clearly demonstrates that SDS GEOS runs very efficiently on Oracle Exadata Database Machine and that SDS is a future-proof and secure partner for the highest workloads.

Oracle Exadata Optimized is part of the Oracle Exastack Optimized program which enables partners, such as SDS, to leverage OPN enablement resources and dedicated lab environments to help develop, test, and tune their applications on Oracle Exadata engineered systems.

By achieving Oracle Exadata Optimized status, Oracle recognizes SDS for developing, testing, and tuning SDS GEOS on Oracle Exadata. This accomplishment is a testament to SDS’s ability to deliver the extreme performance and reliability customers require.

"Together with Oracle, SDS was able to test a new performance dimension in the processing of securities orders. This is a very important indicator that shows the limits of the performance of banking systems and associated transaction service providers can be surpassed, especially when needed in a volatile and strongly crisis-driven trading environment. A level of around 100 to 400 orders per second is usually sufficient for large securities traders in the most significant financial markets in Europe to guarantee their customers an immediate dispatch to the trading center even in times of extremely high order volumes. This requirement was outperformed by up to 700% in our laboratory test, providing clear evidence that SDS GEOS runs very efficiently on Oracle and that SDS is a future-proof and secure partner for the highest workloads in this technology stack," comments SDS Managing Director Ernst Kendlbacher on the results for Oracle Exastack Optimized.

“Oracle Exastack Optimized recognizes partners who have optimized their solutions on a complete, integrated and cloud-ready infrastructure in order to help them accelerate innovation, unlock new features and functionality, and deliver superior value to users,” said David Hicks, Vice President, Worldwide ISV Ecosystem Business Development, Oracle. “By achieving Oracle Exadata Optimized status, SDS has demonstrated that SDS GEOS is tested and tuned to work with Oracle Exadata to help deliver optimum performance, scalability, and reliability to their customers.”

To find out more, please visit http://www.sds.at or http://www.oracle.com/partners/goto/exastack or http://www.oracle.com/partners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rückfragehinweise / Press Contact:
HERBERT REINISCH
Marketing Manager Europe
Software Daten Service Gesellschaft m.b.H.
Rennweg 97-99, 1030 Vienna, Austria
Mobile: +43 676 88241 5188
herbert.reinisch@sds.at

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye